Chyren Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 06-12-2024
- Paid Up Capital ₹ 4.80 M
as on 06-12-2024
- Company Age 3 Year, 4 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.40 Cr
as on 06-12-2024
About Chyren Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.80 M.
The company currently has active open charges totaling ₹1.40 Cr.
Amit Dhankar, Vikas Punia, and Vivek Narwal serve as directors at the Company.
- CIN/LLPIN
U24290HR2021PTC097084
- Company No.
097084
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Aug 2021
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Company Details
- Location
Panchkula, Haryana, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Chyren Pharmaceuticals Private Limited offer?
Chyren Pharmaceuticals Private Limited offers a wide range of products and services, including Digestive System Drugs & Medicines, Antacid Drugs, Ayurvedic,Herbal Products & Medicine, Ayurvedic Herbal Syrups & Tonics, Nutraceuticals & Dietary Supplements, Multivitamin Syrup & Drops, Vitamin Tablets & Capsules, Sexual Wellness Products, Fertility Enhancer.
Who are the key members and board of directors at Chyren Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Amit Dhankar  | Director | 18-Aug-2021 | Current |
| Vikas Punia | Director | 18-Aug-2021 | Current |
| Vivek Narwal | Director | 03-Jan-2022 | Current |
Financial Performance of Chyren Pharmaceuticals.
Enhance accessibility to Chyren Pharmaceuticals's financial data by unlocking access to both Standalone and Consolidated balance sheets, Profit & Loss Statements, Ratios, Related Party Transactions, and additional relevant information.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Chyren Pharmaceuticals?
Unlock access to Chyren Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 27 Jun 2023 | ₹2.50 M | Open |
Canara Bank Creation Date: 05 Jun 2022 | ₹1.15 Cr | Open |
How Many Employees Work at Chyren Pharmaceuticals?
Chyren Pharmaceuticals has a workforce of 0 employees as of Apr 01, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Chyren Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Chyren Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
